Find Bardoxolone Methyl manufacturers, exporters & distributors on PharmaCompass

Bardoxolone-methyl

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

9 Drugs in Development

9 Drugs in Development

DIGITAL CONTENT

20 NEWS #PharmaBuzz

media
20 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

9DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 218600-53-4, Cddo-me, Cddo methyl ester, Rta 402, Nsc 713200, Cddo-methyl ester

Molecular Formula

C₃₂H₄₃NO₄

Molecular Weight

505.7 g/mol

InChI Key

WPTTVJLTNAWYAO-KPOXMGGZSA-N

FDA UNII

CEG1Q6OGU1

Bardoxolone Methyl is the methyl ester form of bardoxolone, a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2), two enzymes involved in inflammation and carcinogenesis. This agent also inhibits the interleukin-1 (IL-1)-induced expression of the pro-inflammatory proteins matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13) and the expression of Bcl-3; Bcl-3 is an IL-1-responsive gene that preferentially contributes to MMP-1 gene expression.

1 2D Structure

Bardoxolone Methyl

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate

2.1.2 InChI

InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1

2.1.3 InChI Key

WPTTVJLTNAWYAO-KPOXMGGZSA-N

2.1.4 Canonical SMILES

CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)OC)C

2.1.5 Isomeric SMILES

C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC

2.2 Other Identifiers

2.2.1 UNII

CEG1Q6OGU1

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 2-cyano-3,12-dioxoolean-1,9-dien-28-oic Acid Methyl Ester

2. Cddo Methyl Ester

3. Cddo-me

4. Methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate

5. Rta-402

2.3.2 Depositor-Supplied Synonyms

1. 218600-53-4

2. Cddo-me

3. Cddo Methyl Ester

4. Rta 402

5. Nsc 713200

6. Cddo-methyl Ester

7. Rta-402

8. Nsc713200

9. Rta402

10. Methyl (4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate

11. Tp-155

12. Ceg1q6ogu1

13. Bardoxolone Methyl [usan]

14. Nsc-713200

15. Methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate

16. 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic Acid Methyl Ester

17. Methyl (4as,6ar,6bs,12as,14ar,14br)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylate

18. Bardoxolone-methyl

19. (4as,6ar,6bs,8ar,12as,14ar,14bs)-methyl 11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicene-4a-carboxylate

20. Mfcd11983137

21. Ncgc00186460-01

22. Bardoxolone (methyl)

23. Bardoxolone Methyl Ester

24. Unii-ceg1q6ogu1

25. Cddo-me, 2

26. Dsstox_cid_28690

27. Dsstox_rid_82960

28. Dsstox_gsid_48764

29. Methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate

30. Gtpl3443

31. Bardoxolone Methyl (jan/usan)

32. Bardoxolone Methyl [jan]

33. Chembl1762621

34. Dtxsid5048764

35. Schembl12521530

36. Chebi:177406

37. 2-cyano-3,12-dioxoolean-1,9-dien-28-oic Acid Methyl Ester

38. 2-cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Methyl Ester

39. Bdbm217379

40. Bardoxolone Methyl [who-dd]

41. Bcp04660

42. Zinc3982151

43. Tox21_113229

44. S8078

45. Bardoxolone Methyl Ester [mi]

46. Akos025401880

47. Ccg-269743

48. Cs-0598

49. Db05983

50. Cddo Methyl Ester, >=98% (hplc)

51. Ac-26830

52. Csa:218600-53-4;bardoxolone Methyl

53. Hy-13324

54. Cas-218600-53-4

55. D09585

56. Nsc 713200; Rta 402; Cddo Methyl Ester

57. A847580

58. Q4860208

59. (+)-methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate

60. (4as,6ar,6bs,8ar,12as,14bs)-methyl 11-cyano-2,2,6a,6b,9,9,12a-he

61. Oleana-1,9(11)-dien-28-oic Acid, 2-cyano-3,12-dioxo-, Methyl Ester

2.4 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₃₂H₄₃NO₄
Molecular Weight	505.7 g/mol
XLogP3	6.7
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	2
Exact Mass	505.31920885 g/mol
Monoisotopic Mass	505.31920885 g/mol
Topological Polar Surface Area	84.2 Å²
Heavy Atom Count	37
Formal Charge	0
Complexity	1210
Isotope Atom Count	0
Defined Atom Stereocenter Count	7
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.

Treatment of Alport syndrome

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

RTA 402 inhibits the activity of nuclear factor kappa-B (NF-kB) activated by tumor necrosis factor (TNF) and other inflammatory agents in a variety of cancer cells. It is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and noncancerous cells by modulating oxidative stress response pathways. As a result, the drug is toxic to cancer cells but induces protective antioxidant and anti-inflammatory responses in normal cells.

Drugs in Development